Pfizer, a world leader in clinical trial innovation, has joined the TriNetX global health research network. As a member, Pfizer will have access to clinical data from TriNetX’s network of healthcare organizations to support clinical study and protocol design, site identification, and patient recruitment for clinical trials across a range of therapeutic areas and development stages.
TriNetX is a global health research network that connects healthcare organizations, biopharmaceutical companies, and contract research organizations (CROs) to collaborate, enhance trial design, accelerate patient recruitment, conduct in-depth research, and help bring new therapies to market faster. Through TriNetX’s cloud-based platform, researchers are able to analyze patient populations and perform “what-if” analyses in real-time. Users of the platform are presented with aggregate views, but each data point in the TriNetX network can be traced to healthcare organizations who have the ability to identify patients, allowing clinical researchers to develop virtual patient cohorts for potential recruitment into a clinical trial.
The TriNetX network will help Pfizer to recruit hard-to-find patients with rare diseases and to identify sites with access to patients who meet inclusion and exclusion criteria.